Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Srimathi Srinivasan

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Blood Advances|January 25, 2023
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trialPeter W M Johnson, Sriram Balasubramanian, Brendan Hodkinson, et al.
Angiogenesis|June 11, 2015
Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesisSrimathi Srinivasan, Vipul Chitalia, Rosana D Meyer, et al.
Blood Advances|June 14, 2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE studyCarol Moreno, Isabelle G Solman, Constantine S Tam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2023
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase InhibitionAlan Cooper, Sravya Tumuluru, Kyle Kissick, et al.
Frontiers in Immunology|September 14, 2020
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma CellsChen Zhu, Zhili Song, Anlai Wang, et al.
EMBO Molecular Medicine|December 31, 2013
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasisMathilde Romagnoli, Nora D Mineva, Michael Polmear, et al.
Blood Advances|December 21, 2022
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trialG A Amos Burke, Luciana Vinti, Edita Kabickova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
The Lancet. Oncology|November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialCarsten U Niemann, Talha Munir, Carol Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW StudyTalha Munir, Carol Moreno, Carolyn Owen, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Blood Advances|January 25, 2023
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trialPeter W M Johnson, Sriram Balasubramanian, Brendan Hodkinson, et al.
Angiogenesis|June 11, 2015
Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesisSrimathi Srinivasan, Vipul Chitalia, Rosana D Meyer, et al.
Blood Advances|June 14, 2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE studyCarol Moreno, Isabelle G Solman, Constantine S Tam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2023
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase InhibitionAlan Cooper, Sravya Tumuluru, Kyle Kissick, et al.
Frontiers in Immunology|September 14, 2020
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma CellsChen Zhu, Zhili Song, Anlai Wang, et al.
EMBO Molecular Medicine|December 31, 2013
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasisMathilde Romagnoli, Nora D Mineva, Michael Polmear, et al.
Blood Advances|December 21, 2022
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trialG A Amos Burke, Luciana Vinti, Edita Kabickova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
The Lancet. Oncology|November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialCarsten U Niemann, Talha Munir, Carol Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW StudyTalha Munir, Carol Moreno, Carolyn Owen, et al.
Pageof 3